Disclosed are 2-(phenylamino)-3H-imidazo[4,5-b]pyridine-6-carboxamide derivatives as represented by te general formula (I), wherein Q2, Q3, Q3a and Q4 each represent C(R2), C(R3), C(R3a) and C(R4) or any one or two of Q2, Q3, Q3a and Q4 may alternatively and independently represent N and wherein the remaining substituents are as defined herein. Representative compounds include 2-(2,6-dichloro-phenylamino)-3H-imidazo[4,5-b]pyridine-6-carboxylic acid (4-chloro-3-fluoro-phenyl)-amide N-(4-bromophenyl )-2 -(2,6-dichlorophenylamino)-5-methoxy-3-methyl-3H-imidazo[4,5-b]pyridine-6-carboxamide 2-(2,6-dichlorophenylamino)-N-(spiro[2.5]octan-6-yl)-3H-imidazo[4,5-b]pyridine-6-carboxamide 2-(4-trifluoromethyl-pyridin-3-ylamino)-5-(2,2-difluoro-ethoxy)-N-(trans-4-trifluoromethyl-cyclohexyl)-3-methyl-3H-imidazo[4,5-b]pyridine-6-carboxamide and 2-(2,6-dichloro-4-fluoro-phenylamino)-5-(2,2,2-trifluoro-ethoxy)-N-(2,2,3,3,4,4,5,5,5-nonafluoropentyl)-3-methyl-3H-imidazo[4,5-b]pyridine-6-carboxamide. Further disclosed is a pharmaceutical which comprises a compound as defined above for the treatment of asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, inflammatory bowel disease, irritable bowel syndrome, pain, inflammatory pain, fever, migraine, headache, low back pain, fibromyalgia, a myofascial disorder, a viral infection, a bacterial infection, a fungal infection, dysmenorrhea, a burn, a surgical or dental procedure, a malignancy, hyperprostaglandin E syndrome, classic Bartter syndrome, atherosclerosis, gout, arthritis, osteoarthritis, juvenile arthritis, rheumatoid arthritis, rheumatic fever, ankylosing spondylitis, Hodgkins disease, systemic lupus erythematosus, vasculitis, pancreatitis, nephritis, bursitis, conjunctivitis, iritis, scleritis, uveitis, wound healing, dermatitis, eczema, psoriasis, stroke, diabetes mellitus, a neurodegenerative disorder, an autoimmune disease, an allergic disorder, rhinitis, an ulcer, coronary heart disease, sarcoidosis, any other di
